Trial Profile

A first-in-human clinical study of HTX-001 in nonobstructive hypertrophic cardiomyopathy

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 May 2025 According to a HAYA Therapeutics media release, the company has raised 65 million dollars in Series A funding, which will be used to initiate clinical trials for HTX-001, a first-in-class lncRNA-targeting therapy for heart failure, initially focused on non-obstructive hypertrophic cardiomyopathy (nHCM).
02 May 2025 According to a HAYA Therapeutics media release, Comapny will showcase its latest advances in HTX-001 at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans from May 13-17, 2025.
03 Jul 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com